Stage (next event)
Phase 1/2a (Data)
Catalyst Info & Data Links
TITLE: VBI-1901 for Glioblastoma Multiforme (GBM / glioblastoma) - Phase 1/2A Data
ClinicalTrial.gov (NCT03382977) Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
WHAT IS THE NEXT CATALYST EVENT?
Phase 1/2A Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Q4 2020 (see slide 4)
Mechanism of Action
MECHANISM OF ACTION / RATIONALE
VBI has applied its eVLP Platform in the development of a glioblastoma multiforme (“GBM” or “glioblastoma”) therapeutic vaccine candidate. With its novel approach, VBI intends to create a GBM immunotherapy that will stimulate the patient’s own immune system to identify and kill GBM cancer cells, with the goal of creating a commercially-viable therapy that is more effective and tolerable than current treatments. VBI has initiated a multi-center, open-label, dose-escalation Phase 1/2a study to evaluate VBI-1901 in patients with recurrent GBM (Learn more HERE).
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post